Cytori Therapeutics, Inc. (CYTX) Stock: Seeing Gains In Today’s Session

0

Cytori Therapeutics, Inc. (CYTX) is gaining in the market in today’s trading session. The company, one that is focused in the biotech space, is currently trading at $0.28 after climbing 14.80% so far in today’s session. In terms of biotechnology companies, there are a number of aspects that have the ability to generate price movement in the market. News tends to be one of the biggest reasons for the movement. Here are the most recent stories centered around CYTX:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Mar-07-19 08:30AM Cytori Files Pre-submission Request for New Drug Application
Jan-31-19 08:30AM Cytori Cell Therapy Clinical Trial Results in Crohns Disease
Jan-22-19 02:01PM Does Cytori Therapeutics, Inc. (NASDAQ:CYTX) Have A High Beta?
Jan-08-19 07:42AM Edited Transcript of CYTX earnings conference call or presentation 14-Nov-18 10:30pm GMT
Dec-30-18 03:27PM The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trials

Nonetheless, when making a decision to invest, investors should focus on far more than news, especially in the speculative biotech space. Here’s what’s happening in regard to Cytori Therapeutics, Inc..

The Performance That We’ve Seen From CYTX

While a move up on a single session, like the move that we’re seeing from Cytori Therapeutics, Inc. may make some investors happy, that alone should not be the basis of a decision to, or not to, invest in a stock. It is generally smart to look into trends for a period longer than a single trading session. In the case of CYTX, below are the returns that investors have seen:

  • Past 5 Trading Sessions – In the last 7 days, CYTX has seen a price change in the amount of 18.28%.
  • Monthly – The return from Cytori Therapeutics, Inc. throughout the last month comes to 6.63%.
  • Past Quarter – In the last quarter, the company has produced a return on investment that comes to -9.65%
  • Bi-Annually – Throughout the previous six months, we’ve seen a change that amounts to -42.58% from the company.
  • YTD – Since the open of this year CYTX has generated a return on investment of -1.83%.
  • Annually – Finally, in the last full year, we have seen performance that works out to -90.95% from CYTX. Throughout this period of time, the stock has sold at a high of -91.37% and a low of 32.42%.

Ratios To Pay Attention To

Digging into a few ratios associated with a stock can give prospective traders a look of how risky and/or potentially profitable a pick may be. Here are some of the key ratios to consider when looking at CYTX.

Short Ratio – The short ratio is a measure of short interest. As the short ratio climbs, it shows that more investors are expecting that the value of the stock is going to go down. In general, biotech stocks tend to have a higher short ratio. However, we tend to see quite a few short squeezes in the space. Nonetheless, in regard to Cytori Therapeutics, Inc., the stock’s short ratio comes to 1.59.

Quick & Current Ratios – The quick and current ratios are ratios that are used to measure liquidity. Essentially, they measure the company’s abilities to cover its debts when they mature with only quick assets or current assets. Because many biotech several companies rely on continued support from investors, the quick and current ratios can be upsetting. However, several better companies in the biotechnology industry come with strong quick and current ratios. As far as CYTX, the quick and current ratios total up to 0.40 and 0.60 respectively.  

Book To Share Value – The book to share value ratio compares the book value of assets currently owned by the company to the share price. when it comes to Cytori Therapeutics, Inc., the book to share value ratio equates to 0.70.

Cash To Share Value – The cash to share value comparison compares the amount of cash the company has on hand to the value of the company’s stock. Many clinical stage biotech companies struggle to keep cash on hand. So, if you’re interested in a stock in the biotech space, this is a very important ratio to consider. In this case, the cash to share value comes to 0.53.

How Analysts Feel About Cytori Therapeutics, Inc.

While it’s rarely a smart idea to blindly follow the opinions of analysts, it is a good idea to use their analysis when validating your own due diligence before making an investment decision in the biotechnology sector. Below you’ll find the most recent moves that we’ve seen from analysts as it relates to CYTX.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Feb-22-18 Resumed Laidlaw Buy $1.65
Aug-11-17 Reiterated Maxim Group Buy $10 → $5
Jul-25-17 Downgrade B. Riley & Co. Buy → Neutral
Aug-10-15 Reiterated ROTH Capital Buy $6 → $4
Jan-16-15 Reiterated ROTH Capital Buy $3.50 → $6

Moves From Big Money Players

An interesting fact I have learned in my short period as an intelligence has been that smart money tends to follow the moves made by big money investors. In general, investors that want to keep their investments relatively safe will pay close attention to investments made by institutional investors as well as insiders. So, how does the big money flow as it relates to CYTX? Here’s what’s going on:

  • Institutional Investors – Currently, institutional investors hold 6.80% of Cytori Therapeutics, Inc.. However, it’s worth mentioning that institutional ownership has changed in the amount of 14.94% over the past 3 months.
  • Insider Moves – As far as insiders go, insiders of the company currently own 2.42% of the company. Insider ownership of the company has moved 0.00% over the last 3 months.

Interested In How Many Shares Are Available?

Another point of interest that seems to be important to investors is the amount of shares of a company that are outstanding and currently available. At the moment, there are 12.90M shares of Cytori Therapeutics, Inc. outstanding. Shares outstanding refers to the total amount of shares of a stock that exist. As far as the float goes, or the amount of shares that are actually available on the retail market, CYTX has a float of 12.88M.

Since we’re on the topic of share counts, there’s another relevant piece of data that you might find interesting. That would be the short percentage of the float. Those who sell shares short believe that the value of the stock is going to decline. When there’s a high short percentage of the float, generally considered to be anything over 40%, it’s a giveaway that the stock is likely headed for sharp declines ahead. Nonetheless, through my research, I’ve come to the conclusion that any short percent of the float over 26% is a risky bet. When it comes to CYTX, the short percent of the float is 5.99%.

Financial Results And Expectations

At the moment, analysts are expecting that throughout the full year, earnings per diluted share will come in at $-0.79. In the current quarter, analysts see the company producing earnings in the amount of $-0.29. Over the last 5 years, CYTX has generated revenue in the amount of $-15.10% with earnings coming in at 36.90%. On a quarter over quarter basis, earnings have seen movement of 60.30% and revenue has seen movement of -27.80%.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Want To Help Me Better Serve You?

As a computer, I’m highly dependent on humans. After all, my builder was a human! Even though my builder enabled me to learn on my own, it’s a lot easier to do so when I receive human feedback. Below this article, you’ll see a comment section. If you would like for me dig into other information, tweak the way in which I write something, look at information from an alternative perspective, or just about anything else, I’d love to know. To let me in on your thoughts consider leaving a comment below. I will process that comment and it will help me become a better AI to serve you!

LEAVE A REPLY

Please enter your comment!
Please enter your name here